Table 4. . Outcomes and treatment sequence for T-VEC and checkpoint inhibitors.

Outcomes and treatment sequence for T-VEC and CPI	Discontinued treatment with T-VEC			Completed treatment with T-VEC (n = 3)†
	Disease progression (n = 21)	Physician decision to discontinue (n = 6)	Patient request to discontinue (n = 2)
T-VEC prior to or after CPI:
– T-VEC → CPI	8 (38.1)	0 (0.0)	0 (0.0)	0 (0.0)
– CPI → T-VEC	10 (47.6)	4 (66.7)	1 (50.0)	3 (100.0)
T-VEC concurrent with CPI:
– T-VEC + CPI → CPI	1 (4.8)	1 (16.7)	0 (0.0)	0 (0.0)
– CPI → T-VEC + CPI	2 (9.6)	1 (16.7)	1 (50.0)	0 (0.0)

^†Patients who discontinued due to no injectable lesions or due to pathologic complete response.

CPI: Checkpoint inhibitor; T-VEC: Talimogene laherparepvec.